Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
Status:
Active, not recruiting
Trial end date:
2022-06-25
Target enrollment:
Participant gender:
Summary
This single arm, open label, two stage study will be conducted in several medical centers
around Taiwan. Stage one determine safety and tolerability in patients with HCC, and stage
two assess anti-tumor activities of GT90001 in combination with nivolumab in patients with
metastatic HCC. Subjects who fulfill all the entry criteria and have written informed consent
will be enrolled to the study.